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Abstract: Very low-calorie diets (VLCDs) are an effective means by which to induce 
 clinically significant weight loss. However, their acceptance by health care practitioners and 
the public is generally lower than that for other nonsurgical weight loss methods. Whilst there is 
currently little evidence to suggest they have any detrimental effect on hepatic and renal health, 
data assessing these factors remain limited. We carried out a systematic review of the literature on 
randomized controlled trials that had a VLCD component and that reported outcomes for hepatic 
and renal health, published between January 1980 and December 2012. Cochrane criteria were fol-
lowed, and eight out of 196 potential articles met the inclusion criteria. A total of 548 participants 
were recruited across the eight studies. All eight studies reported significant weight loss fol-
lowing the VLCD. Changes in hepatic and renal outcomes were variable but generally led 
to either no change or improvements in either of these. Due to the heterogeneity in the quality 
and methodology of the studies included, the effect of VLCDs on hepatic and renal outcomes 
remains unclear at this stage. Further standardized research is therefore required to fully assess 
the impact of VLCDs on these outcome measures, to better guide clinical practice.
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Introduction
The prevalence of overweight and obesity is increasing globally, and effective weight 
loss treatment is of great importance from both a health and socioeconomic perspective.1 
Very low-calorie diets (VLCDs) are an effective means by which to induce a clinically 
significant weight loss.2 However, their acceptance by health care practitioners and the 
public, in general, is much lower than that for other nonsurgical weight loss methods. 
This is likely to be due to the adverse effects of the nutritionally insufficient VLCDs 
that were popular in the 1970s, which resulted in a number of deaths due to vitamin 
and mineral deficiencies and consumption of poor quality or inadequate amounts of 
protein.3,4 The VLCDs of the past were, however, completely different from the nutri-
tionally replete variants of modern day VLCDs, and despite the fact that fast weight 
loss, seen in followers of a VLCD, is still generally perceived as being unsafe, there 
is no convincing evidence to suggest that this is the case. Indeed, the European Food 
Safety Authority has approved a health claim with regards to the efficacy of VLCDs 
on weight loss, in a target population of obese adults.5
A VLCD is defined as a diet of ,800 kcal/day,6 and there are many commercially 
available variants that provide energy intakes between 300−800 kcal/day.
There is sufficient evidence in the literature to ensure the safe use of VLCDs in 
healthy overweight and obese patients in the short term;7,8 however, there remains 
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limited evidence on the effects of VLCDs on specific disease 
groups over this same period of time. This is likely to, in part, 
be due to the strict protocols and monitoring that are advised 
with this type of dietary approach to weight loss. Although 
the evidence for the benefits of VLCDs is mounting in cer-
tain groups of individuals at higher cardiovascular risk, for 
example those with type 2 diabetes mellitus,9,10 there is little 
evidence of outcomes in patients with other obesity-related 
secondary diseases, such as nonalcoholic fatty liver disease 
(NAFLD). In a recent review, Mulholland et al,2 investigating 
long-term (.12 months) randomized control trials of VLCD, 
identified only two reports of studies that evaluated effects on 
liver and kidney function.11,12 One paper11 described that at 
2 years follow up, there were no significant changes in liver 
transaminases. The other paper12 reported both statistically 
and biologically significant improvements in both hepatic and 
renal health, including changes in alanine aminotransferase, 
alkaline phosphatase, γ-Glutamyl transferase, creatinine, 
estimated glomerular filtration rate (eGFR), and urea. The 
observed changes in liver enzymes indicated an improvement 
in hepatic steatosis and an improvement in the biochemical 
markers associated with renal and hepatic pathology.
Furthermore, a recent study by Lim et al13 reported that in 
patients with type 2 diabetes mellitus who followed a VLCD, 
the resulting acute negative energy balance reversed the type 
2 diabetes mellitus by normalizing both insulin sensitivity 
and beta cell function. The authors suggested this result was 
due to the reduction of fat in the liver and pancreas. These 
results are in keeping with our previous findings, which 
demonstrated improvements in liver enzymes following a 
VLCD.12
Whilst there is currently little evidence to suggest VLCDs 
cause any detriment to liver or kidney health, data assessing 
these factors remain limited. Thus, we aimed to carry out a 
systematic review of the literature and of studies investigating 
a VLCD and reporting outcomes for liver and kidney health, 
published between January 1980 and December 2012.
Methods
The protocol used for this systematic review follows the 
methods recommended by the Cochrane Collaboration.14 
Further details of the approach are described below.
Inclusion criteria
This review was intended to assess the literature in this field. 
Studies from January 1980 to December 2012 were  evaluated. 
Studies prior to 1980 were not included, due to health con-
cerns associated with the formulations of the VLCDs in the 
1970s.3,4 Only investigations of adult (18 years and over) 
participants with a mean or median body mass index (BMI) 
of $28 kg/m2 were included, and only randomized, controlled 
trials with a VLCD component were evaluated.  Variations 
in the duration of the intervention which were aimed at 
achieving weight loss (ie, active weight loss prior to weight 
maintenance approaches) were recorded and accounted for, 
where possible.
Types of interventions
The focus of this review was to examine the effect of VLCDs 
on hepatic and renal outcomes. The types of dietary interven-
tions evaluated were VLCDs (also known as very low-energy 
diets), defined as a dietary intake of 800 kcal/day or less.
Outcome measures
Weight loss was the main outcome assessed in the studies 
included in the review. With regard to hepatic or renal status, 
the following outcomes were also included:
•	 Liver enzymes (alanine aminotransferase [ALT], alkaline 
phosphatase [ALKP], aspartate transaminase [AST], 
gamma-glutamyl transpeptidase [GGT], and albumin)
•	 Electrolytes and markers of urea and kidney function 
(sodium, potassium, chloride, creatinine, and eGFR)
•	 NAFLD.
Search strategy for the identification  
of included studies
This systematic review was restricted to studies where the full 
study report was available. A search strategy on MEDLINE was 
applied to identify as many as possible of the studies evaluating 
dietary interventions using VLCDs and relevant to hepatic and 
renal status. The search strategy incorporated the terms “very 
low calorie diet” and “very low energy diet.” Authors were 
contacted for further details of their trials and the reference lists 
of included studies and reviews were also searched.
Quality assessment of studies
The protocol used for the quality assessment followed the 
methods recommended by Avenell et al.15 The studies were 
classified as having either a low risk of bias (A), an unclear 
risk of bias (B), or a high risk of bias (C). The subset “I” 
suggested that a description was provided, while the subset 
“II” suggested that no description was provided.
Full copies of studies were assessed by two researchers, 
for methodological quality. The researchers were not blinded 
to the author, journal, or institution. Differences of opinion 
were resolved by discussion. The trial quality was assessed 
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and included a consideration of whether or not the analysis 
was undertaken on an intention-to-treat basis.
Identified studies
A total of eight out of 196 articles met the inclusion criteria 
and were included in the systematic review. The reasons for 
the exclusion of studies are summarized in Figure 1.
Results
Study characteristics
A total of 548 participants were recruited across the eight 
studies included in this systematic review. There was a large 
amount of heterogeneity in the study design for the papers 
meeting the inclusion criteria. The studies included ranged 
from 8 weeks16 to 2 years11 in duration. The duration of the 
VLCDs ranged from 25 days11 to 9 months.12 In the follow-up 
phase, different studies incorporated aspects of behavior 
modification,11 reduced calorie intake,17−19 or medication 
(acarbose) (Table 1).20
All of the studies were designed to reduce weight or prevent 
weight gain and also examined hepatic and renal outcomes. 
The results of all the studies are summarized in Table 1.
Quality assessment
Table 2 displays the quality assessment of the reported 
 studies. All of the studies were randomized, but the allocation 
 description was generally not provided, with the exception of 
one paper,21 in which the method of concealment had a real 
chance of disclosure of assignment prior to formal trial entry. 
Four studies11,18−20 clearly stated the numbers and reasons for 
withdrawal from the study, while two studies12,21 only pro-
vided the numbers of withdrawals, and two studies16,17 made 
no mention of dropouts. Three studies analyzed the data with 
the intention to treat,12,20,21 while three16,17,19 may also have done 
so, but the methods of analysis were unclear, and the final two 
studies11,18 presented data for completers only.  Participants as 
well as health care providers were blinded to the treatment in 
two studies (of a test emulsion,18 and acarbose,20 respectively); 
participants were not blinded in the other six studies, and it 
was unclear whether the health care providers or the outcome 
assessors were blinded to treatment status.
Weight change
All eight of the studies resulted in significant weight loss 
following the VLCD period (Table 2). Where weight change 
was reported after a follow-up period, the implementation 
of any of a reduced-calorie diet,17 regular support through 
intensive or less intensive behavior modification therapy,11 
meal replacement once a day,18 or ongoing use of VLCD12 
resulted in the maintenance of significant weight loss com-
pared with baseline. Although no values for weight change 
were provided, Hauner et al20 stated that the use of acarbose 
resulted in individuals remaining at a stable weight for the 
weeks following the VLCD (Table 2).
hepatic outcomes
Table 3 displays the results for different hepatic outcomes 
reported in three of the studies. Arai et al16 observed an 
improvement in AST and ALT following the VLCD.  Rolland 
et al12 also reported an improvement in ALT as well as in 
ALKP, GGT, and albumin following the VLCD period. 
Melin et al11 provided baseline values but only anecdotally 
reported (ie, no values were presented) that there were no 
changes in the liver transaminases.
Two other studies reported anecdotal results of changes 
in hepatic outcomes. Olsson et al18 reported that ALT levels 
increased significantly during the weight-reduction phase but 
were normalized during the 12-week weight maintenance 
phase, whereas Hauner et al20 reported that no changes were 
observed in the serum transaminases in participants undergo-
ing a VLCD followed by the use of acarbose.
Only one study investigated the effect of VLCDs on 
NAFLD. In the study by Lin et al,21 41 participants with 
NAFLD were placed on a 450 kcal/day VLCD for 12 weeks. 
Total number of references
(n = 196)
Excluded based on titles and abstracts
Not VLCD (n = 15) 
Not RCT (n = 95) 
No liver/kidney outcomes (n = 57) 
Duplicates excluded
(n = 2)
Titles and abstracts screening
(n = 194)
Potential papers eligible for
inclusion (n = 27)
Total studies included for
review (n = 8)
Not in accordance with inclusion criteria (n = 19)
Not RCT (n = 8) 
No liver/kidney outcomes (n = 11) 
Figure 1 Summary of the literature search.
Abbreviations: rCT, randomized controlled trial; VLCD, very low-calorie diet.
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Table 1 Summary of studies included in the review
Author N  
(males)
Study Mean BMI  
(kg/m2)
Inclusion criteria Duration  
of VLCD
Duration of  
follow up
Weight (kg)  
at baseline
Weight (kg) at the  
end of the VLCD  
period
Weight (kg) at the  
end of the follow up
Arai  
et al16
45 (12) rCT in which patients undertook either 
1.  Supplemental LCD (3515−5021 kJ/d with use of 2−3 packages of Optifast 70 and  
2678−3682 kJ of conventional balanced meals consisting of a mixture of 88 g p,  
30−80 g ChO, 4−9 g F) or
2.  VLCD where participants used 5 packages of Optifast 70 (daily energy intake of 1757 kJ,  
70 g protein, 30 g ChO, 2 g F)
 
SLCD: 31.9 (4.4) 
 
 
VLCD: 32.9 (6.1)
Overweight adult men  
and women
8 weeks –  
SLCD: 81.5 (14.0) 
 
 
VLCD: 82.0 (20.0)
 
SLCD: 76.3 (14.7)a 
 
 
VLCD: 73.0 (16.3)a
–
Doherty  
et al17
26 (0) rCT in which patients received either 
1. Control: diet of their choosing throughout the 45 weeks (control); 
2.  VLCD: 1 week of a 1200 kcal/d BDD and a 420 kcal/d liquid diet for weeks 2−17. patients  
were realimented during weeks 18−24 by increasing the daily caloric intake by extra  
~150 kcal for each week of realimentation until reaching ∼1150 kcal/d at week 24. patients  
were instructed to consume a balanced diet providing 1200−1500 kcal/d for the remainder  
of the treatment (weeks 26−45)
3.  BDD + exercise: consume a BDD providing 1000−1500 kcal/d (15%−20% protein;  
50%−55% ChO, 30% fat) for 45 weeks. Instructed (at week 8) to begin a program of aerobic  
activity (mostly consisting of walking). Initially10−20 minutes two to three times per week.  
By end of study, they reported exercising for 20−40 minutes three to five times per week
 
Control: 33.4 (2) 
VLCD: 40.4 (2) 
 
 
 
BDD: 36.5 (2)
Obese women 15 weeks 29 weeks  
Control: 94.7 (5.0) 
 
 
VLCD: 111.2 (5.0) 
 
BDD + exercise:  
102.8 (6)
 
Control: Δ 2.7 (1.2) 
 
 
VLCD: Δ −21.3 (2.1)a,d 
 
BDD + exercise: 
Δ −10.3 (2.7)a,d
 
Control: Δ 3.9 (2.3) 
 
 
VLCD: Δ −22.4 (3.4)a,d 
 
BDD + exercise: 
Δ −14.5 (5.5)a,d
hauner  
et al20
110 (22) rCT in which patients underwent a pretreatment phase of VLCD/LCD  
(700−1000 kcal/d) to achieve a weight loss of at least 2–3 BMI units. Afterwards, participants  
were asked to maintain an individually tailored weight-maintaining diet and were either  
prescribed a placebo or acarbose (treatment started with 50 mg once/day and titrated up  
to a maximum of 100 mg tid at weekly intervals)
placebo: 34.8 (2.2) 
Acarbose: 34.7 (2.3)
Weight stable  
obese subject with  
BMI 32−38 kg/m2
10−16 weeks 26 weeks placebo: 97.8 (13.0) 
Acarbose: 97.7 (13.5)
No values placebo: Δ 0.6 kg 
Acarbose: weight stable 
(no values)
Lin et al21 132 (43) rCT in which patients undertook a 2-week introduction phase during which they consumed  
a 1200 kcal/d diet. This was followed by a 450 kcal/d VLCD or an 800 kcal/d VLCD for  
10 weeks
VLCD 450: 34.4 (3.5) 
VLCD 800: 34.1 (3.9)
Obese (BMI $30 kg/m2)  
Taiwanese between the ages  
of 18−65 years
10 weeks – 450 kcal/d: 92.5 (14.1) 
800 kcal/d: 92.1 (15.6)
450 kcal/d: 
Δ −8.37 (0.70)b 
800 kcal/d: 
Δ −8.42 (0.70)b
–
Melin  
et al11
43 (4) rCT in which patients undertook a 25-day VLCD followed by hypocaloric diet. patients  
were divided into two groups 
Group 1: intensive behavior modification therapy every fortnight during the first year and  
six meetings in the second year 
Group 2: planned meetings every third month
 
 
Group 1: 35.6 (4.5) 
 
Group 2: 35.2 (4.6)
Men and women;  
24−60 years old;  
BMI 35 kg/m2 (29−48)
25 days 2 years  
 
Group 1: 99.8 (5.5) 
 
Group 2: 93.4 (4.1)
 
 
Group 1: 
Δ	−8.3 (0.64)b 
Group 2: 
Δ −10.0 (0.71)b
 
 
Group 1: Δ −6.8  
(1.4)a 
Group 2: 
Δ −8.6 (1.6)a
Olsson  
et al18
43 (0) rCT in which patients were assigned to a 6-week VLCD to achieve at least a 5% reduction  
in body weight, after which they resumed habitual eating patterns except for lunch, which  
was replaced by Nutrilett® Intensive meal (111 kcal) mixed with a control or a test emulsion
Control: 28.3 (1.6) 
emulsion: 28.2 (1.4)
Female; 18−60 years;  
BMI 26−31 kg/m2
6 weeks 12 weeks Control: 79.0 (8.3) 
Test emulsion: 79.7 (6.1)
Control: 71.5 (7.1)a 
Test emulsion: 73.0 (5.3)a
Control: 70.2 (6.9)a 
emulsion: 72.0 (5.6)a
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120 (11) RCT where patients were assigned to a 600 calorie-deficit diet for 3 months. Those who did not  
achieve a 5% weight loss were randomized to either: LChp or VLCD for the following 9 months
LChp: 41.6 (4.8) 
VLCD: 46.0 (7.0)
Men and women; .18 years  
old; BMI $35 kg/m2
6.9 months  
(4−9 months)
– LChp: 110.4 (12.2) 
VLCD: 129.6 (23.0)
– LChp: 109.1 (14.6) 
VLCD: 98.0 (20.3)c,e
ryttig and  
rössner19
60 (11) rCT in which patients were assigned to 12 weeks of VLCD followed by a gradual increase  
of normal food during 1 week. After transition, patients were assigned to either: 
Group 1: normal, well-balanced hypocaloric diet containing 1600 kcal/d, of which 220 kcal  
was provided by two sachets of the Cambridge diet 
Group 2: normal, well-balanced hypocaloric diet containing 1600 kcal/d of solid food only
 
 
Group 1: 38.0 (4.9) 
 
Group 2: 40.3 (6.0)
Obese men and women (BMI $30  
kg/m2), between 19−65 years,  
with stable body weight within  
the previous 2 months (less than 
3 kg fluctuation)
12 weeks 52 weeks Solid food:  
120.1 (22.5)e 
Meal replacement:  
108.1 (15.8)
Solid food: 
97.6 (19.1)a,d 
Meal replacement:  
85.7 (14.7)a
No significant change 
during the weight 
maintenance period 
between the groups  
(no values provided)
Notes: Values are reported as mean (standard deviations), unless stated otherwise. Δ represents a change. aP , 0.05 from baseline; bP , 0.001 from baseline; cP , 0.0001 
from baseline; dP , 0.05 between groups; eP , 0.001 between groups.
Abbreviations: BDD, balanced deficient diet; BMI, body mass index; CHO, carbohydrate; F, fat; kJ/d, kilojoules per day; LCD, low-calorie diet; LCHP, low carbohydrate high 
protein; p, protein; rCT, randomized controlled trial; Se, standard error; SLCD, supplemental low-calorie diet; tid, three times daily; VLCD, very low-calorie diet.
In this group, a 41.5% improvement rate in NAFLD was 
reported, where five of the 41 participants no longer had 
NAFLD, and others had improvements in severity; how-
ever, of the five participants in this group who did not 
have NAFLD at the beginning of the intervention, two 
had developed NAFLD by the end of the intervention. 
Lin et al21 also had participants on an 800 kcal/d VLCD. 
In this latter group, they observed a 50% improvement 
rate, where of the 42 participants who initially presented 
with NAFLD, ten no longer had NAFLD, and of the five 
participants who did not have NAFLD at baseline, none 
developed it.
renal outcomes
Table 4 displays the results of the renal outcomes from the 
only paper12 that provided values for changes in renal  function. 
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Table 1 Summary of studies included in the review
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(kg/m2)
Inclusion criteria Duration  
of VLCD
Duration of  
follow up
Weight (kg)  
at baseline
Weight (kg) at the  
end of the VLCD  
period
Weight (kg) at the  
end of the follow up
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8 weeks –  
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were realimented during weeks 18−24 by increasing the daily caloric intake by extra  
~150 kcal for each week of realimentation until reaching ∼1150 kcal/d at week 24. patients  
were instructed to consume a balanced diet providing 1200−1500 kcal/d for the remainder  
of the treatment (weeks 26−45)
3.  BDD + exercise: consume a BDD providing 1000−1500 kcal/d (15%−20% protein;  
50%−55% ChO, 30% fat) for 45 weeks. Instructed (at week 8) to begin a program of aerobic  
activity (mostly consisting of walking). Initially10−20 minutes two to three times per week.  
By end of study, they reported exercising for 20−40 minutes three to five times per week
 
Control: 33.4 (2) 
VLCD: 40.4 (2) 
 
 
 
BDD: 36.5 (2)
Obese women 15 weeks 29 weeks  
Control: 94.7 (5.0) 
 
 
VLCD: 111.2 (5.0) 
 
BDD + exercise:  
102.8 (6)
 
Control: Δ 2.7 (1.2) 
 
 
VLCD: Δ −21.3 (2.1)a,d 
 
BDD + exercise: 
Δ −10.3 (2.7)a,d
 
Control: Δ 3.9 (2.3) 
 
 
VLCD: Δ −22.4 (3.4)a,d 
 
BDD + exercise: 
Δ −14.5 (5.5)a,d
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(700−1000 kcal/d) to achieve a weight loss of at least 2–3 BMI units. Afterwards, participants  
were asked to maintain an individually tailored weight-maintaining diet and were either  
prescribed a placebo or acarbose (treatment started with 50 mg once/day and titrated up  
to a maximum of 100 mg tid at weekly intervals)
placebo: 34.8 (2.2) 
Acarbose: 34.7 (2.3)
Weight stable  
obese subject with  
BMI 32−38 kg/m2
10−16 weeks 26 weeks placebo: 97.8 (13.0) 
Acarbose: 97.7 (13.5)
No values placebo: Δ 0.6 kg 
Acarbose: weight stable 
(no values)
Lin et al21 132 (43) rCT in which patients undertook a 2-week introduction phase during which they consumed  
a 1200 kcal/d diet. This was followed by a 450 kcal/d VLCD or an 800 kcal/d VLCD for  
10 weeks
VLCD 450: 34.4 (3.5) 
VLCD 800: 34.1 (3.9)
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Taiwanese between the ages  
of 18−65 years
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Group 1: intensive behavior modification therapy every fortnight during the first year and  
six meetings in the second year 
Group 2: planned meetings every third month
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24−60 years old;  
BMI 35 kg/m2 (29−48)
25 days 2 years  
 
Group 1: 99.8 (5.5) 
 
Group 2: 93.4 (4.1)
 
 
Group 1: 
Δ	−8.3 (0.64)b 
Group 2: 
Δ −10.0 (0.71)b
 
 
Group 1: Δ −6.8  
(1.4)a 
Group 2: 
Δ −8.6 (1.6)a
Olsson  
et al18
43 (0) rCT in which patients were assigned to a 6-week VLCD to achieve at least a 5% reduction  
in body weight, after which they resumed habitual eating patterns except for lunch, which  
was replaced by Nutrilett® Intensive meal (111 kcal) mixed with a control or a test emulsion
Control: 28.3 (1.6) 
emulsion: 28.2 (1.4)
Female; 18−60 years;  
BMI 26−31 kg/m2
6 weeks 12 weeks Control: 79.0 (8.3) 
Test emulsion: 79.7 (6.1)
Control: 71.5 (7.1)a 
Test emulsion: 73.0 (5.3)a
Control: 70.2 (6.9)a 
emulsion: 72.0 (5.6)a
rolland  
et al12
120 (11) RCT where patients were assigned to a 600 calorie-deficit diet for 3 months. Those who did not  
achieve a 5% weight loss were randomized to either: LChp or VLCD for the following 9 months
LChp: 41.6 (4.8) 
VLCD: 46.0 (7.0)
Men and women; .18 years  
old; BMI $35 kg/m2
6.9 months  
(4−9 months)
– LChp: 110.4 (12.2) 
VLCD: 129.6 (23.0)
– LChp: 109.1 (14.6) 
VLCD: 98.0 (20.3)c,e
ryttig and  
rössner19
60 (11) rCT in which patients were assigned to 12 weeks of VLCD followed by a gradual increase  
of normal food during 1 week. After transition, patients were assigned to either: 
Group 1: normal, well-balanced hypocaloric diet containing 1600 kcal/d, of which 220 kcal  
was provided by two sachets of the Cambridge diet 
Group 2: normal, well-balanced hypocaloric diet containing 1600 kcal/d of solid food only
 
 
Group 1: 38.0 (4.9) 
 
Group 2: 40.3 (6.0)
Obese men and women (BMI $30  
kg/m2), between 19−65 years,  
with stable body weight within  
the previous 2 months (less than 
3 kg fluctuation)
12 weeks 52 weeks Solid food:  
120.1 (22.5)e 
Meal replacement:  
108.1 (15.8)
Solid food: 
97.6 (19.1)a,d 
Meal replacement:  
85.7 (14.7)a
No significant change 
during the weight 
maintenance period 
between the groups  
(no values provided)
Notes: Values are reported as mean (standard deviations), unless stated otherwise. Δ represents a change. aP , 0.05 from baseline; bP , 0.001 from baseline; cP , 0.0001 
from baseline; dP , 0.05 between groups; eP , 0.001 between groups.
Abbreviations: BDD, balanced deficient diet; BMI, body mass index; CHO, carbohydrate; F, fat; kJ/d, kilojoules per day; LCD, low-calorie diet; LCHP, low carbohydrate high 
protein; p, protein; rCT, randomized controlled trial; Se, standard error; SLCD, supplemental low-calorie diet; tid, three times daily; VLCD, very low-calorie diet.
The results demonstrated an improvement in creatinine, urea, 
and eGFR levels in response to a VLCD.
Two other studies reported anecdotal outcomes for renal 
function. Doherty et al17 reported that there were no signifi-
cant changes in potassium, sodium, or chloride observed at 
45 weeks in response to a VLCD followed by a balanced 
deficit diet. Similarly, Ryttig and Rössner19 reported that 
there were no significant changes in serum electrolytes 
(sodium, potassium) at the end of the 12 weeks of VLCD 
or during the weight maintenance period, between the two 
groups (balanced hypocaloric diet with or without a meal 
replacement component).
Discussion
As expected from previous studies, the VLCD interventions 
resulted in significant weight loss. The changes in hepatic and 
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Table 2 Quality assessment of included rCTs
Quality of  
random allocation  
concealment
Description of  
withdrawals  
and dropouts
Intention  
to treat?
Participants  
blinded to  
treatment status?
Healthcare providers  
blinded to treatment  
status?
Outcome assessors  
blinded to treatment 
status?
Arai et al16 B (I) C B C B (I) B (I)
Doherty et al17 B (I) C B C B (I) B (I)
hauner et al20 B (I) A A A (II) A (II) B (I)
Lin et al21 B (II) B (I) A C B (I) B (I)
Melin et al11 B (I) A C C B (I) B (I)
Olsson et al18 B (I) A C A (II) A (II) B (I)
rolland et al12 B (I) B (I) A C B (I) B (I)
ryttig and  
rössner19
B (I) A B C B (I) B (I)
Notes: A = low risk of bias; B = unclear risk of bias; C = high risk of bias. Subset “I” suggests that a description was provided, while subset “II” suggests that no description 
was provided.
Abbreviation: rCT, randomized controlled trial.
Table 3 Summary of liver results
Author Patient groups AST (IU/L) ALT (IU/L) ALKP (IU/L) GGT (IU/L) Total bilirubin (mol/L) Albumin (g/L)
Pre Post- 
VLCD
Study 
end
Pre Post- 
VLCD
Study  
end
Pre Post- 
VLCD
Study end Pre Post-VLCD Study end Pre Post-VLCD Study end Pre Post-VLCD Study end
Arai 
et al16
SLCD 
VLCD
26.3 (24.5) 
22.9 (18.3)
16.0 (6.4) 
12.6 (4.7)c
– 35.2 (39.5) 
27.6 (20.7)
13.0 (8.3) 
14.1 (9.8)c
– – – – – – –
Melin  
et al11
Group 1: intensive 
Group 2: less  
intensive
29.4 (5.9) 
29.4 (5.9)
– No Δ 29.4 (11.8) 
29.4 (11.8)
– No Δ – – – 30.0 (24.0) 
24.0 (12.0)
– No Δ
rolland  
et al12
VLCD 
LChp
– 
–
– 
–
– 
–
30. 0 (17.8) 
35.4 (23.0)
– 
–
23.2 (8.9)a,b 
34.5 (27.7)
81.6 (19.6) 
89.1 (32.9)
– 
–
77.3 (23.0)a 
84.6 (26.7)
33.8 (33.7) 
48.2 (77.4)
– 
–
24.1 (17.7)a,b 
39.6 (51.2)
9.1 (5.8) 
10.0 (3.6)
– 
–
9.8 (7.3) 
9.4 (5.1)a
43.0 (2.5) 
45.0 (2.4)
– 
–
42.8 (2.2)a 
45.6 (5.8)
Notes: Values are reported as means. Δ represents a change. aP , 0.05 from baseline; bP , 0.05 between groups; clikely to be significantly different from baseline, but no 
P-value provided.
Abbreviations: ALT, alanine aminotransferase; ALKp, alkaline phosphatase; AST, aspartate transaminase; GGT, gamma-glutamyl transpeptidase; LChp, low carbohydrate, 
high protein diet; SLCD, supplemental; VLCD, very low-calorie diet.
renal outcomes resulting from the weight loss achieved using 
the VLCDs were variable, but generally, there was either no 
change or an improvement in hepatic and renal health. This 
may be due to the fact that these studies measuring kidney 
and liver outcomes only included adults with normal kidney 
and liver function, with the exception of NAFLD.
The outcomes in terms of hepatic function were improved 
in some studies, remained the same in others, and initially 
increased during the VLCD phase but normalized thereafter in 
one study. The inconsistencies between these studies are 
likely to be due to a combination of things, including the 
different lengths of treatment, different sampling times, as 
well as different weight maintenance approaches. However, 
these  studies certainly did not demonstrate any negative 
outcomes for hepatic health in response to a VLCD and sub-
sequent follow up. On the contrary, when looking at the out-
comes for NAFLD, the effect of the weight loss achieved by the 
VLCD resulted in important improvements in NAFLD, most 
likely due to the associated decrease in visceral  adiposity.22 
These results are supported by our earlier findings12 and 
suggestion that changes in liver enzymes may indicate an 
improvement in hepatic steatosis. Several other studies have 
also suggested beneficial effects of weight loss on liver size 
and adiposity. Colles et al23 observed that during a 12-week 
VLCD, most of the reduction in liver size occurred in the first 
2 weeks of weight loss, likely due to the depletion of liver 
glycogen and bound water (caused by the low carbohydrate 
content of the diet).24 Favorable changes were also observed 
in a range of biochemical and clinical tests (significant 
decreases in ALKP, bilirubin, ALT, and GGT). Andersen 
et al25 investigated the effects of weight loss induced by a 
VLCD on liver morphology and function in morbidly obese 
but otherwise healthy individuals. They observed a marked 
improvement in hepatic health, which correlated with the 
reduction of weight. However, they also observed that 24% 
of the patients developed a slight portal inflammation as 
well as, in 12% of patients, a slight portal fibrosis. They 
did not find predictors (morphological or biochemical) for 
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Table 3 Summary of liver results
Author Patient groups AST (IU/L) ALT (IU/L) ALKP (IU/L) GGT (IU/L) Total bilirubin (mol/L) Albumin (g/L)
Pre Post- 
VLCD
Study 
end
Pre Post- 
VLCD
Study  
end
Pre Post- 
VLCD
Study end Pre Post-VLCD Study end Pre Post-VLCD Study end Pre Post-VLCD Study end
Arai 
et al16
SLCD 
VLCD
26.3 (24.5) 
22.9 (18.3)
16.0 (6.4) 
12.6 (4.7)c
– 35.2 (39.5) 
27.6 (20.7)
13.0 (8.3) 
14.1 (9.8)c
– – – – – – –
Melin  
et al11
Group 1: intensive 
Group 2: less  
intensive
29.4 (5.9) 
29.4 (5.9)
– No Δ 29.4 (11.8) 
29.4 (11.8)
– No Δ – – – 30.0 (24.0) 
24.0 (12.0)
– No Δ
rolland  
et al12
VLCD 
LChp
– 
–
– 
–
– 
–
30. 0 (17.8) 
35.4 (23.0)
– 
–
23.2 (8.9)a,b 
34.5 (27.7)
81.6 (19.6) 
89.1 (32.9)
– 
–
77.3 (23.0)a 
84.6 (26.7)
33.8 (33.7) 
48.2 (77.4)
– 
–
24.1 (17.7)a,b 
39.6 (51.2)
9.1 (5.8) 
10.0 (3.6)
– 
–
9.8 (7.3) 
9.4 (5.1)a
43.0 (2.5) 
45.0 (2.4)
– 
–
42.8 (2.2)a 
45.6 (5.8)
Notes: Values are reported as means. Δ represents a change. aP , 0.05 from baseline; bP , 0.05 between groups; clikely to be significantly different from baseline, but no 
P-value provided.
Abbreviations: ALT, alanine aminotransferase; ALKp, alkaline phosphatase; AST, aspartate transaminase; GGT, gamma-glutamyl transpeptidase; LChp, low carbohydrate, 
high protein diet; SLCD, supplemental; VLCD, very low-calorie diet.
these changes and hypothesized that a fast mobilization of 
intracellular triacylglycerols and subsequent secretion of fatty 
acids had induced a portal inflammation, which in turn, led 
to the fibrosis. They proposed that a rapid mobilization of 
intra- and extrahepatic fat stores may present a hepatotoxic 
factor common to all weight loss treatments that induce rapid 
weight loss. Based on their observations, they postulated that 
to avoid the development of portal fibrosis during treatment 
with VLCD, a weight loss slower than 1.6 kg/week should 
be recommended.
The issue of the development of fibrosis in the study by 
Andersen et al25 should not be confused with the development 
of fibrosis observed in individuals following bariatric surgery, 
another approach that induces rapid weight loss. Several 
studies have reported improvements in liver biochemical 
and histological outcomes following bariatric surgery,26−28 
but some authors have expressed concern that rapid weight 
loss may be a causative factor in the occurrence of fibrosis 
that was observed.27−29 However, as Kral et al28 suggest, this 
may be due to a decreased serum albumin and poorly man-
aged diarrhea, which are two known potential side effects of 
certain types of bariatric surgery. The problems with hepatic 
fibrosis are well known30 and are probably not related to the 
rate of weight loss but rather, to surgically induced short 
bowel syndrome. Certainly, the issue of fibrosis did not figure 
in the clinical trials highlighted in this systematic review, and 
such situations are not generally associated with the use of 
low-calorie diet or VLCD interventions.
Limited information was available regarding the response 
of renal function to the weight loss induced by VLCD. 
 Nevertheless, the current data suggest either an improve-
ment or no change in response to weight loss induced 
by a VLCD followed by a weight maintenance period. 
Previously, we suggested that improvements in renal function 
during a VLCD are possible, due to the associated increase 
in fluid intake and/or reduction in creatine intake.12
Obesity-related glomerular disease was first identified by 
Weisinger et al31 in the 1970s, and the prevalence of obesity-
related glomerulopathy has been increasing as a consequence 
of the obesity epidemic.32 It has been suggested that reducing 
the glomerular hyperfiltration observed in the obese may 
provide a way to prevent or delay the development of renal 
disease in these individuals.33 Indeed, Chagnac et al33 demon-
strated improvements in GFR following weight loss induced 
by a gastroplasty. This finding is supported by the review by 
Navaneethan et al,34 in which the researchers reported that in 
patients with chronic kidney disease, bariatric surgery was 
associated with a decrease in BMI, with resultant normaliza-
tion of glomerular hyperfiltration; however, they also stated 
that it remains to be clarified whether this normalization can 
result in long-term renal benefits. Previously, we reported 
an improvement in eGFR following the VLCD.12 The use of 
eGFR, however, is a poor indicator of improved renal func-
tion in this case − as a direct result of the use of VLCDs, the 
intake of creatine drops dramatically, and hence, the serum 
creatinine also drops, and this may give a false impression of 
improved renal function. Also, the use of eGFR significantly 
underestimates measured kidney function with obesity, and 
measuring changes in eGFR when body surface area is also 
changing is problematic.35
In addition, the use of eGFR has not been validated in 
patients with normal kidney function.
Strengths and limitations
The main limitation of this review is the small number of 
studies included as well as the lack of data presented in many 
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of the studies. In addition, the heterogeneity of the studies in 
terms of study quality, treatment duration, outcomes mea-
sured, and time points rendered it impossible to carry out 
a meta-analysis. It is also important to highlight that only 
one study16 reported hepatic outcomes, and none reported 
renal outcomes immediately post-VLCD (or during active 
VLCD) compared with follow up (long after the VLCD was 
completed).
Finally, in assessing kidney function outcomes, it would 
have been beneficial to have information about renal blood 
flow, arterial pressure, and albuminuria.
Conclusion
There are currently no effective treatments for NAFLD other 
than weight reduction and lifestyle modification.36,37 The 
effect of VLCDs on hepatic and renal outcomes remains 
unclear at this stage. There have been a number of improve-
ments observed in terms of hepatic and renal outcomes; 
however, there may be some concern about the onset of 
fibrosis in some individuals, although no evidence for this 
was observed in the current systematic review. Renal out-
comes seem little affected by VLCDs; however, the studies 
measuring kidney function included only adults with normal 
kidney function, and the results cannot be extrapolated to 
those with any degree of kidney dysfunction. At this stage, 
further standardized research is required to fully assess the 
impact of VLCDs on hepatic and renal health and to better 
advise clinical practice.
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